♥

Aurobindo Pharma Limited

ISIN : INE406A01037
NSE : AUROPHARMA
BSE : 524804
Face Value : 1
Industry : Pharmaceuticals & Drugs

EPS : 54.16
EPS (TTM) : 60.07
Price to Earning (P/E) : 21.43
Book Value : 509.35
Price to Bookvalue (P/B) : 2.28
Dividend Yield : 0 %
Return on Equity (ROE) : 11.18 %
Return on Capital Employed (ROCE) : 13.76 %

Aurobindo Pharma share price (02-Apr-2026)
National Stock Exchange NSE
Open / Close	0 - 0 NAN %
Low / High	0 - 0 NAN %
Trade Volume	0
52 Week Low / High	0 - 0 NAN %
Bombay Stock Exchange BSE
Open / Close	1341.95 - 1335.95 -0.4 %
Low / High	1265.75 - 1341.95 6 %
Trade Volume	54,134
52 Week Low / High	1017 - 1359 33.6 %

YOU MAY ALSO LIKE

Share Market basics for beginners
Share Market jargons in simple terms
Low PE ratio stocks
Undervalued, low PE ratio stocks on Stock exchange NSE and BSE
How much money do you need to retire
Know how much money do you need to retire, before how much to invest ?
Stock market course tutorial
Stock Market Investment Course explained in simple words.
High dividend stocks
High dividend yield stocks on Stock exchange NSE and BSE
CAGR Calculator
Check your investment returns using our CAGR / Investment Growth Calculator

Consolidated Standalone

CONSOLIDATED QUARTERLY RESULT FOR AUROBINDO PHARMA LIMITED

Date End	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
No of months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months
Net Sales	58093.7	62359.2	57393.7	64071.3	64729.6	68505.2	72194.2	73517.8	75801.5	75670.2
Total Income	58582.5	62765.4	57965.6	64997.8	66078.7	69668.5	74064	75143	77157.7	77879.5
Total Expenditure	48349.7	52994.4	49485.8	54527.2	54707.8	56991.5	58459.8	57504.7	59073.4	59474.5
Other Income	488.8	406.2	571.9	926.5	1349.1	1163.3	1869.8	1625.2	1356.2	2209.3
Operating Profit	10232.8	9771	8479.8	10470.6	11370.9	12677	15604.2	17638.3	18084.3	18405
Interest	92.1	146.3	252.9	449.6	556	565.5	681.8	755.5	894.3	1110.4
Exceptional Items	-1627.6					-697.5			-1221.1
PBDT	8513.1	9624.7	8226.9	10021	10814.9	11414	14922.4	16882.8	15968.9	17294.6
Depreciation	2535.7	2795.1	2981	3214	3455.7	3265.6	4175	4232.7	3543.3	4041.8
Profit Before Tax	5977.4	6829.6	5245.9	6807	7359.2	8148.4	10747.4	12650.1	12425.6	13252.8
Tax	174.9	1586.1	1129.9	1891	2241.5	2423.2	3237	3224.5	3225.5	4056.7
Profit After Tax	5802.5	5243.5	4116	4916	5117.7	5725.2	7510.4	9425.6	9200.1	9196.1
Net Profit	5802.5	5243.5	4116	4916	5117.7	5725.2	7510.4	9425.6	9200.1	9196.1
Equity Capital	585.9	585.9	585.9	585.9	585.9	585.9	585.9	585.9	585.9	585.9
Face Value (IN RS)	1	1	1	1	1	1	1	1	1	1
Calculated EPS	9.84	8.88	6.99	8.38	8.64	9.74	12.92	15.98	15.51	15.69
Diluted Eps After Extraordinary Items	9.84	8.88	6.99	8.38	8.64	9.74	12.83	16.04	15.51	15.69
Diluted Eps Before Extraordinary Items	9.84	8.88	6.99	8.38	8.64	9.74	12.83	16.04	15.51	15.69

STANDALONE QUARTERLY RESULT FOR AUROBINDO PHARMA LIMITED

Date End	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
No of months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months
Net Sales	28871.7	27869.2	30256.6	34322.6	35474.4	23908.2	26687.6	26920.3	28940.3	24600.9
Total Income	33005.4	28256.3	30815.2	35109.9	38356.1	24857	27358.4	30231.6	30170	25254.1
Total Expenditure	23802	25446.6	27297.6	29590.4	28556.1	19684.4	21235.8	22103.4	21192.4	19611.6
Other Income	4133.7	387.1	558.6	787.3	2881.7	948.8	670.8	3311.3	1229.7	653.2
Operating Profit	9203.4	2809.7	3517.6	5519.5	9800	5172.6	6122.6	8128.2	8977.6	5642.5
Interest	49.1	78.5	192	389.6	489.7	315.9	366.9	612.5	530.7	511.3
Exceptional Items	-747.1
PBDT	8407.2	2731.2	3325.6	5129.9	9310.3	4856.7	5755.7	7515.7	8446.9	5131.2
Depreciation	1012.2	1030.5	1088	1085	1150	596.3	657.9	643.5	648.1	668.8
Profit Before Tax	7395	1700.7	2237.6	4044.9	8160.3	4260.4	5097.8	6872.2	7798.8	4462.4
Tax	-626.6	479.1	591.3	1056.7	1712.3	1080.4	1301.3	634.4	2012.1	1172
Profit After Tax	8021.6	1221.6	1646.3	2988.2	6448	3180	3796.5	6237.8	5786.7	3290.4
Net Profit	8021.6	1221.6	1646.3	2988.2	6448	3359.5	4157.4	6237.8	5786.7	3290.4
Equity Capital	585.9	585.9	585.9	585.9	585.9	585.9	585.9	585.9	585.9	585.9
Face Value (IN RS)	1	1	1	1	1	1	1	1	1	1
Calculated EPS	13.69	2.09	2.81	5.1	11.01	5.43	6.48	10.65	9.88	5.62
Diluted Eps After Extraordinary Items	13.69	2.08	2.81	5.1	11	5.43	6.48	10.65	9.88	5.62
Diluted Eps Before Extraordinary Items	13.69	2.08	2.81	5.1	11	5.43	6.48	10.65	9.88	5.62

Consolidated Standalone

CONSOLIDATED ANNUAL RESULT FOR AUROBINDO PHARMA LIMITED

Date End	Mar 2022	Mar 2023	Mar 2024
No of months	12 months	12 months	12 months
Net Sales	234555	248554	290019
Total Income	237758	251460	295592
Total Expenditure	190687	211367	231589
Other Income	3203.5	2905.9	5573.8
Operating Profit	47071.2	40092.3	64003.8
Interest	486.4	1404.8	2897.1
Exceptional Items	-1279.7		-1918.6
PBDT	45305.1	38687.5	59188.1
Depreciation	11265.2	12445.8	15216.6
Profit Before Tax	34039.9	26241.7	43971.5
Tax	7256.3	6848.5	12110.2
Profit After Tax	26783.6	19393.2	31861.3
Net Profit	26783.6	19393.2	31861.3
Equity Capital	585.9	585.9	585.9
Face Value (IN RS)	1	1	1
Reserves	245174	267813	297842
Calculated EPS	45.2	32.9	54.16
Diluted Eps After Extraordinary Items	45.19	32.9	54.16
Diluted Eps Before Extraordinary Items	45.19	32.9	54.16

STANDALONE ANNUAL RESULT FOR AUROBINDO PHARMA LIMITED

Date End	Mar 2022	Mar 2023	Mar 2024
No of months	12 months	12 months	12 months
Net Sales	112871	127923	106456
Total Income	119581	132260	112617
Total Expenditure	98137.4	110614	84216
Other Income	6709.9	4337.6	6160.6
Operating Profit	21443.9	21646.8	28401
Interest	169.4	1149.8	1826
Exceptional Items	-747.1
PBDT	20527.4	20497	26575
Depreciation	4152.6	4353.5	2545.8
Profit Before Tax	16374.8	16143.5	24029.2
Tax	1827.7	3839.4	5028.2
Profit After Tax	14547.1	12304.1	19001
Net Profit	14547.1	12304.1	19541.4
Equity Capital	585.9	585.9	585.9
Face Value (IN RS)	1	1	1
Reserves	170588	178556	196642
Calculated EPS	24.83	21	32.43
Diluted Eps After Extraordinary Items	24.83	21	32.43
Diluted Eps Before Extraordinary Items	24.83	21	32.43

Consolidated Standalone

CONSOLIDATED PROFIT / LOSS FOR AUROBINDO PHARMA LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Gross Sales	48589.8 Cr	47811.7 Cr	50860.1 Cr	59784.1 Cr
Sales	48238 Cr	47480.5 Cr	50109.1 Cr	59005.5 Cr
Processing Charges / Service Income	135.14 Cr	242.24 Cr	512.75 Cr	481.2 Cr
Net Sales	24774.6 Cr	23455.5 Cr	24855.4 Cr	29001.9 Cr
Increase/Decrease in Stock	-730.21 Cr	816.68 Cr	-409.68 Cr	-946.17 Cr
Raw Material Consumed	9557.92 Cr	8422.23 Cr	10600.2 Cr	12295 Cr
Opening Raw Materials	2434.42 Cr	3027.58 Cr	2378.15 Cr	2681.44 Cr
Purchases Raw Materials	7821.05 Cr	5817.32 Cr	8853.02 Cr	9760.72 Cr
Closing Raw Materials	3012.97 Cr	2374.44 Cr	2681.44 Cr	2920.14 Cr
Other Direct Purchases / Brought in cost	2315.42 Cr	1951.77 Cr	2050.43 Cr	2772.93 Cr
Power & Fuel Cost	589.28 Cr	626.86 Cr	842.63 Cr	826.03 Cr
Electricity & Power	589.28 Cr	626.86 Cr	842.63 Cr	826.03 Cr
Employee Cost	3535.02 Cr	3450.92 Cr	3522.25 Cr	3922.94 Cr
Salaries, Wages & Bonus	3069.52 Cr	3021.32 Cr	3072.98 Cr	3413.25 Cr
Contributions to EPF & Pension Funds	143.69 Cr	149.81 Cr	159 Cr	228.34 Cr
Workmen and Staff Welfare Expenses	243.67 Cr	213.49 Cr	228.36 Cr	184.36 Cr
Other Manufacturing Expenses	2875.39 Cr	2502.98 Cr	2810.03 Cr	3191.71 Cr
Processing Charges	65.12 Cr	26.57 Cr	35.92 Cr	80.04 Cr
Repairs and Maintenance	335.86 Cr	356.93 Cr	384.46 Cr	429.08 Cr
Packing Material Consumed	1074.76 Cr	901.37 Cr	1102.78 Cr	1254.12 Cr
General and Administration Expenses	1473.59 Cr	1335.03 Cr	1386.66 Cr	1534.59 Cr
Rent , Rates & Taxes	211.61 Cr	227.08 Cr	241.86 Cr	203.6 Cr
Insurance	89.1 Cr	112.6 Cr	121.32 Cr	130.65 Cr
Printing and stationery	33.98 Cr	31.93 Cr	32.22 Cr	35.76 Cr
Professional and legal fees	1017.4 Cr	841.78 Cr	875.45 Cr	1030.03 Cr
Traveling and conveyance	47.38 Cr	52.7 Cr	81.81 Cr	98.66 Cr
Selling and Distribution Expenses	1564.17 Cr	1496.67 Cr	1685.76 Cr	1684.72 Cr
Sales Commissions & Incentives	244.75 Cr	280.01 Cr	134.25 Cr	154.51 Cr
Freight and Forwarding	838.32 Cr	772.94 Cr	1086.71 Cr	950.08 Cr
Miscellaneous Expenses	576.06 Cr	419.58 Cr	698.93 Cr	650.1 Cr
Bad debts /advances written off	28.16 Cr	0	0	7 Cr
Provision for doubtful debts	0	0	52.45 Cr	17.27 Cr
Loss on disposal of fixed assets(net)	141.12 Cr	40.02 Cr	0	0
Loss on foreign exchange fluctuations	0	0	39.58 Cr	0
Total Expenditure	19441.2 Cr	19071 Cr	21136.7 Cr	23158.9 Cr
Other Income	380.85 Cr	322.58 Cr	290.59 Cr	557.38 Cr
Interest Received	16.5 Cr	31.6 Cr	137.34 Cr	285.76 Cr
Dividend Received	0	3.37 Cr	2.63 Cr	2.54 Cr
Profit on sale of Fixed Assets	0	0	13.23 Cr	23.49 Cr
Profits on sale of Investments	0	29.08 Cr	0	10 Lk
Provision Written Back	82.52 Cr	67.79 Cr	13.01 Cr	10.05 Cr
Foreign Exchange Gains	103.58 Cr	69.96 Cr	0	38.78 Cr
Operating Profit	5714.25 Cr	4707.12 Cr	4009.23 Cr	6400.38 Cr
Interest	74.49 Cr	48.64 Cr	140.48 Cr	289.71 Cr
Bank Charges etc	14.92 Cr	11.8 Cr	11.53 Cr	21.62 Cr
PBDT	5639.76 Cr	4658.48 Cr	3868.75 Cr	6110.67 Cr
Depreciation	1055.39 Cr	1126.52 Cr	1244.58 Cr	1521.66 Cr
Profit Before Taxation & Exceptional Items	4584.37 Cr	3531.96 Cr	2624.17 Cr	4589.01 Cr
Exceptional Income / Expenses	2814.58 Cr	-127.97 Cr	0	-191.86 Cr
Profit Before Tax	7398.95 Cr	3403.99 Cr	2612.5 Cr	4379.99 Cr
Provision for Tax	2009.77 Cr	725.63 Cr	684.85 Cr	1211.02 Cr
Current Income Tax	2321.82 Cr	662.82 Cr	1071.48 Cr	1777.54 Cr
Deferred Tax	-312.05 Cr	62.81 Cr	-386.63 Cr	-566.52 Cr
Profit After Tax	5389.18 Cr	2678.36 Cr	1927.65 Cr	3168.97 Cr
Minority Interest	1.02 Cr	1.04 Cr	-15 Lk	4 Cr
Share of Associate	-55.36 Cr	-31.25 Cr	0	0
Consolidated Net Profit	5334.84 Cr	2648.15 Cr	1927.5 Cr	3172.97 Cr
Profit Balance B/F	15042.4 Cr	20136.8 Cr	22519 Cr	23910.4 Cr
Appropriations	20377.2 Cr	22784.9 Cr	24446.5 Cr	27083.4 Cr
Other Appropriation	6.1 Cr	2.23 Cr	257.69 Cr	18.3 Cr
Equity Dividend %	400	900	300	450
Earnings Per Share	91.05	45.2	32.9	54.16
Adjusted EPS	91.05	45.2	32.9	54.16

STANDALONE PROFIT / LOSS FOR AUROBINDO PHARMA LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Gross Sales	15875.8 Cr	11350.3 Cr	12885 Cr	10663.2 Cr
Sales	15662.9 Cr	11122.7 Cr	12499.1 Cr	10288.4 Cr
Processing Charges / Service Income	11.45 Cr	190.58 Cr	201.18 Cr	271.36 Cr
Net Sales	15823.7 Cr	11287.1 Cr	12792.3 Cr	10645.6 Cr
Increase/Decrease in Stock	2.99 Cr	45.51 Cr	-466 Cr	-116.23 Cr
Raw Material Consumed	6420.16 Cr	5233.51 Cr	6686.44 Cr	5249.54 Cr
Opening Raw Materials	2130.86 Cr	2596.95 Cr	1505.71 Cr	1755.84 Cr
Purchases Raw Materials	6860.16 Cr	4125.46 Cr	6847.34 Cr	4392.69 Cr
Closing Raw Materials	2596.95 Cr	1505.71 Cr	1755.84 Cr	1102.39 Cr
Other Direct Purchases / Brought in cost	26.09 Cr	16.81 Cr	89.23 Cr	203.4 Cr
Power & Fuel Cost	512.34 Cr	477.99 Cr	613.92 Cr	191.58 Cr
Electricity & Power	512.34 Cr	477.99 Cr	613.92 Cr	191.58 Cr
Employee Cost	1735.42 Cr	1600.04 Cr	1641.88 Cr	980.56 Cr
Salaries, Wages & Bonus	1587.6 Cr	1464.27 Cr	1504.46 Cr	902.69 Cr
Contributions to EPF & Pension Funds	57.27 Cr	53.53 Cr	54 Cr	33.35 Cr
Workmen and Staff Welfare Expenses	26.32 Cr	24.79 Cr	30.09 Cr	16.03 Cr
Other Manufacturing Expenses	1889.15 Cr	1465.38 Cr	1429.43 Cr	1251.91 Cr
Processing Charges	58.28 Cr	20.47 Cr	27.53 Cr	7.35 Cr
Repairs and Maintenance	209.45 Cr	194.99 Cr	212.02 Cr	111.89 Cr
Packing Material Consumed	821.67 Cr	567.23 Cr	650.48 Cr	714.94 Cr
General and Administration Expenses	424.44 Cr	441.87 Cr	377.42 Cr	282.56 Cr
Rent , Rates & Taxes	27.11 Cr	25.17 Cr	20.97 Cr	15.84 Cr
Insurance	44.32 Cr	48.26 Cr	50.55 Cr	24.38 Cr
Printing and stationery	23.3 Cr	18.11 Cr	18.75 Cr	11.63 Cr
Professional and legal fees	297.12 Cr	327.7 Cr	246.05 Cr	198.82 Cr
Traveling and conveyance	22.04 Cr	12.34 Cr	31.94 Cr	24.57 Cr
Selling and Distribution Expenses	503.78 Cr	375.02 Cr	583.87 Cr	417.19 Cr
Sales Commissions & Incentives	33.09 Cr	21.03 Cr	33.03 Cr	6.61 Cr
Freight and Forwarding	460.99 Cr	332.33 Cr	517.18 Cr	367.68 Cr
Miscellaneous Expenses	215.57 Cr	192.28 Cr	194.4 Cr	164.49 Cr
Bad debts /advances written off	23 Lk	0	0	0
Provision for doubtful debts	0	0	18.63 Cr	11.37 Cr
Loss on disposal of fixed assets(net)	17 Lk	31.09 Cr	0	0
Total Expenditure	11703.8 Cr	9831.6 Cr	11061.4 Cr	8421.6 Cr
Other Income	589.86 Cr	688.85 Cr	433.76 Cr	616.06 Cr
Interest Received	45.77 Cr	77.1 Cr	185.71 Cr	230.07 Cr
Dividend Received	307.46 Cr	450.99 Cr	164.87 Cr	264.67 Cr
Profit on sale of Fixed Assets	0	0	13.35 Cr	1.55 Cr
Provision Written Back	32.12 Cr	26.82 Cr	5.16 Cr	26 Lk
Foreign Exchange Gains	185.44 Cr	122.8 Cr	55.79 Cr	94.26 Cr
Operating Profit	4709.69 Cr	2144.39 Cr	2164.68 Cr	2840.1 Cr
Interest	28.68 Cr	16.94 Cr	114.98 Cr	182.6 Cr
Bank Charges etc	2.72 Cr	1.74 Cr	1.91 Cr	1.92 Cr
PBDT	4681.01 Cr	2127.45 Cr	2049.7 Cr	2657.5 Cr
Depreciation	488 Cr	415.26 Cr	435.35 Cr	254.58 Cr
Profit Before Taxation & Exceptional Items	4193.01 Cr	1712.19 Cr	1614.35 Cr	2402.92 Cr
Exceptional Income / Expenses	0	-74.71 Cr	0	0
Profit Before Tax	4193.01 Cr	1637.48 Cr	1614.35 Cr	2402.92 Cr
Provision for Tax	1080.1 Cr	182.77 Cr	383.94 Cr	502.82 Cr
Current Income Tax	1043.34 Cr	379.7 Cr	407.02 Cr	598.08 Cr
Deferred Tax	36.76 Cr	-196.93 Cr	-23.08 Cr	-95.26 Cr
Profit After Tax	3112.91 Cr	1454.71 Cr	1230.41 Cr	1900.1 Cr
Extra items	0	0	0	54.04 Cr
Consolidated Net Profit	3112.91 Cr	1454.71 Cr	1230.41 Cr	1954.14 Cr
Profit Balance B/F	11799.3 Cr	14671.4 Cr	15864.1 Cr	16660.1 Cr
Appropriations	14912.2 Cr	16126.1 Cr	17094.6 Cr	18614.2 Cr
Other Appropriation	6.42 Cr	-1.69 Cr	257.81 Cr	1.7 Cr
Equity Dividend %	400	900	300	450
Earnings Per Share	53.13	24.83	21	32.43
Adjusted EPS	53.13	24.83	21	32.43

Consolidated Standalone

CONSOLIDATED CASH FLOW FOR AUROBINDO PHARMA LIMITED

Year End	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Profit Before Tax	7343.59 Cr	3372.74 Cr	2612.5 Cr	4379.99 Cr
Adjustment	-1662.64 Cr	1344.13 Cr	1586.47 Cr	1496.24 Cr
Changes In working Capital	-1066.78 Cr	1557.8 Cr	-1094.98 Cr	-1675.07 Cr
Cash Flow after changes in Working Capital	4614.17 Cr	6274.67 Cr	3103.99 Cr	4201.16 Cr
Cash Flow from Operating Activities	3328.92 Cr	5016.48 Cr	2386.75 Cr	2434.52 Cr
Cash Flow from Investing Activities	598.69 Cr	-3211.56 Cr	-3977.75 Cr	-4255.95 Cr
Cash Flow from Financing Activitie	-1364.81 Cr	-2969.27 Cr	1814.41 Cr	800.42 Cr
Net Cash Inflow / Outflow	2562.8 Cr	-1164.35 Cr	223.41 Cr	-1021.01 Cr
Opening Cash & Cash Equivalents	2746.82 Cr	5329.91 Cr	4162.51 Cr	4392.27 Cr
Cash & Cash Equivalent of Subsidiaries under liquidations	22.41 Cr	-3.25 Cr	6.41 Cr	0
Effect of Foreign Exchange Fluctuations	-2.12 Cr	20 Lk	-6 Lk	14.17 Cr
Closing Cash & Cash Equivalent	5329.91 Cr	4162.51 Cr	4392.27 Cr	3385.43 Cr

STANDALONE CASH FLOW FOR AUROBINDO PHARMA LIMITED

Year End	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Profit Before Tax	4193.01 Cr	1637.48 Cr	1614.35 Cr	2475.41 Cr
Adjustment	53.15 Cr	-30.65 Cr	175.19 Cr	69.61 Cr
Changes In working Capital	-624.9 Cr	2811.95 Cr	332.21 Cr	-228.04 Cr
Cash Flow after changes in Working Capital	3621.26 Cr	4418.78 Cr	2121.75 Cr	2316.98 Cr
Cash Flow from Operating Activities	2994.41 Cr	3726.71 Cr	1821.16 Cr	1714.8 Cr
Cash Flow from Investing Activities	-2648.73 Cr	-1613.51 Cr	-3459.68 Cr	-159.96 Cr
Cash Flow from Financing Activitie	-27.94 Cr	-2447.54 Cr	1719.48 Cr	-1837.03 Cr
Net Cash Inflow / Outflow	317.74 Cr	-334.34 Cr	80.96 Cr	-282.19 Cr
Opening Cash & Cash Equivalents	67.35 Cr	383.58 Cr	48.21 Cr	357.13 Cr
Effect of Foreign Exchange Fluctuations	-1.51 Cr	-1.03 Cr	48 Lk	8.38 Cr
Closing Cash & Cash Equivalent	383.58 Cr	48.21 Cr	129.65 Cr	83.32 Cr

Consolidated Standalone

CONSOLIDATED BALANCE SHEET FOR AUROBINDO PHARMA LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Share Capital	58.59 Cr	58.59 Cr	58.59 Cr	58.59 Cr
Equity - Authorised	66 Cr	179.05 Cr	179.05 Cr	179.05 Cr
Equity - Issued	58.59 Cr	58.59 Cr	58.59 Cr	58.59 Cr
Equity Paid Up	58.59 Cr	58.59 Cr	58.59 Cr	58.59 Cr
Face Value	1	1	1	1
Total Reserves	21871.3 Cr	24517.4 Cr	26781.3 Cr	29784.2 Cr
Securities Premium	417.89 Cr	417.89 Cr	417.89 Cr	417.89 Cr
Capital Reserves	81.89 Cr	81.89 Cr	122.13 Cr	122.13 Cr
Profit & Loss Account Balance	20136.8 Cr	22519 Cr	24013 Cr	26801.4 Cr
General Reserves	813.16 Cr	813.16 Cr	813.16 Cr	813.16 Cr
Reserve excluding Revaluation Reserve	21871.3 Cr	24517.4 Cr	26781.3 Cr	29784.2 Cr
Shareholder's Funds	21929.9 Cr	24576 Cr	26839.8 Cr	29842.8 Cr
Minority Interest	-88 Lk	-1.93 Cr	12 Cr	8 Cr
Secured Loans	168.4 Cr	249.21 Cr	618.96 Cr	2134.9 Cr
Term Loans - Banks	168.4 Cr	249.21 Cr	618.96 Cr	2134.9 Cr
Deferred Tax Assets / Liabilities	121.88 Cr	122.37 Cr	-287.88 Cr	-856.08 Cr
Deferred Tax Assets	600.91 Cr	429.74 Cr	768.88 Cr	1335.71 Cr
Deferred Tax Liability	722.79 Cr	552.11 Cr	481 Cr	479.63 Cr
Other Long Term Liabilities	359.78 Cr	359.73 Cr	363.07 Cr	304.42 Cr
Long Term Provisions	157.11 Cr	171.79 Cr	172.72 Cr	225.7 Cr
Total Non-Current Liabilities	807.17 Cr	903.1 Cr	866.87 Cr	1808.94 Cr
Trade Payables	2794.68 Cr	2703.05 Cr	3871.31 Cr	4454.16 Cr
Sundry Creditors	2794.68 Cr	2703.05 Cr	3871.31 Cr	4454.16 Cr
Other Current Liabilities	2685.47 Cr	3106.51 Cr	2979.91 Cr	3070.63 Cr
Advances received from customers	10.68 Cr	562.3 Cr	373.98 Cr	233 Cr
Interest Accrued But Not Due	1.28 Cr	0	79 Lk	2.68 Cr
Short Term Borrowings	4802.71 Cr	2117.83 Cr	4230.43 Cr	4168.54 Cr
Secured ST Loans repayable on Demands	885.06 Cr	288.75 Cr	1927.04 Cr	1821.95 Cr
Working Capital Loans- Sec	885.06 Cr	288.75 Cr	1927.04 Cr	1821.95 Cr
Short Term Provisions	382.29 Cr	228.59 Cr	412.13 Cr	505.8 Cr
Provision for Tax	210.36 Cr	58.03 Cr	211.6 Cr	249.01 Cr
Total Current Liabilities	10665.2 Cr	8155.98 Cr	11493.8 Cr	12199.1 Cr
Total Liabilities	33401.3 Cr	33633.1 Cr	39212.5 Cr	43858.9 Cr
Gross Block	13613.3 Cr	15943.1 Cr	18593.3 Cr	23447.8 Cr
Less: Accumulated Depreciation	4239.75 Cr	5411 Cr	7569.63 Cr	8952.24 Cr
Less: Impairment of Assets	0	0	0	2.74 Cr
Net Block	9373.58 Cr	10532.1 Cr	11023.7 Cr	14492.8 Cr
Capital Work in Progress	2428.89 Cr	2937.56 Cr	4496.4 Cr	2739.39 Cr
Non Current Investments	431.22 Cr	618.3 Cr	391.74 Cr	321.65 Cr
Long Term Investment	431.22 Cr	618.3 Cr	391.74 Cr	321.65 Cr
Quoted	0	317.59 Cr	208.23 Cr	136.45 Cr
Unquoted	431.22 Cr	300.71 Cr	183.51 Cr	185.2 Cr
Long Term Loans & Advances	658.44 Cr	575.33 Cr	794 Cr	714.55 Cr
Other Non Current Assets	53.03 Cr	37.52 Cr	67.39 Cr	255.53 Cr
Total Non-Current Assets	13577.8 Cr	15510.4 Cr	17666.8 Cr	19653.2 Cr
Currents Investments	159.79 Cr	378.85 Cr	151 Cr	50.58 Cr
Quoted	100.79 Cr	378.85 Cr	151 Cr	50.58 Cr
Unquoted	431.22 Cr	300.71 Cr	183.51 Cr	185.2 Cr
Inventories	9026.57 Cr	7553.85 Cr	8511.23 Cr	9808.23 Cr
Raw Materials	3012.97 Cr	2374.44 Cr	2681.44 Cr	2920.14 Cr
Work-in Progress	1302.48 Cr	1197.84 Cr	1406.83 Cr	1577.03 Cr
Finished Goods	2502.38 Cr	2094.86 Cr	2413.11 Cr	3656.32 Cr
Packing Materials	354.98 Cr	340.27 Cr	378.48 Cr	468.33 Cr
Stores and Spare	237.51 Cr	291.98 Cr	322.07 Cr	284.02 Cr
Sundry Debtors	3503.28 Cr	4012.26 Cr	4466.38 Cr	4816.74 Cr
Debtors more than Six months	0	205.28 Cr	195.37 Cr	248.68 Cr
Debtors Others	3598.27 Cr	3899.11 Cr	4392.67 Cr	4691.31 Cr
Cash and Bank	5474.28 Cr	4190.01 Cr	6084.2 Cr	6278.3 Cr
Cash in hand	28 Lk	7.79 Cr	7.95 Cr	26 Lk
Balances at Bank	5474 Cr	4182.22 Cr	6076.25 Cr	6278.04 Cr
Other Current Assets	601.29 Cr	473.05 Cr	554.71 Cr	519.45 Cr
Interest accrued on Investments	9.4 Cr	15.74 Cr	15.02 Cr	19.94 Cr
Short Term Loans and Advances	1058.3 Cr	1514.67 Cr	1692.39 Cr	2298.62 Cr
Advances recoverable in cash or in kind	333.15 Cr	408.76 Cr	490.39 Cr	648.06 Cr
Advance income tax and TDS	78.98 Cr	269.99 Cr	75.62 Cr	5.67 Cr
Total Current Assets	19823.5 Cr	18122.7 Cr	21459.9 Cr	23771.9 Cr
Net Current Assets (Including Current Investments)	9158.36 Cr	9966.71 Cr	9966.13 Cr	11572.8 Cr
Total Assets	33401.3 Cr	33633.1 Cr	39212.5 Cr	43858.9 Cr
Contingent Liabilities	140.83 Cr	157.74 Cr	158.53 Cr	311.34 Cr
Total Debt	4971.11 Cr	2372.77 Cr	4861.52 Cr	6315.22 Cr
Book Value	374.29	419.46	458.1	509.35
Adjusted Book Value	374.29	419.46	458.1	509.35

STANDALONE BALANCE SHEET FOR AUROBINDO PHARMA LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Share Capital	58.59 Cr	58.59 Cr	58.59 Cr	58.59 Cr
Equity - Authorised	66 Cr	179.05 Cr	179.05 Cr	179.05 Cr
Equity - Issued	58.59 Cr	58.59 Cr	58.59 Cr	58.59 Cr
Equity Paid Up	58.59 Cr	58.59 Cr	58.59 Cr	58.59 Cr
Face Value	1	1	1	1
Total Reserves	15866 Cr	17058.8 Cr	17855.6 Cr	19664.2 Cr
Securities Premium	342.73 Cr	342.79 Cr	342.79 Cr	342.79 Cr
Capital Reserves	53.98 Cr	53.98 Cr	53.98 Cr	72.11 Cr
Profit & Loss Account Balance	14671.4 Cr	15864.1 Cr	16661 Cr	18348.9 Cr
General Reserves	788.84 Cr	788.84 Cr	788.84 Cr	788.84 Cr
Reserve excluding Revaluation Reserve	15866 Cr	17058.8 Cr	17855.6 Cr	19664.2 Cr
Shareholder's Funds	15924.6 Cr	17117.3 Cr	17914.2 Cr	19722.8 Cr
Deferred Tax Assets / Liabilities	433.38 Cr	237.03 Cr	215.91 Cr	118.91 Cr
Deferred Tax Assets	68.61 Cr	43.82 Cr	55.24 Cr	47.45 Cr
Deferred Tax Liability	501.99 Cr	280.85 Cr	271.15 Cr	166.36 Cr
Other Long Term Liabilities	74.42 Cr	60.58 Cr	42.91 Cr	21.51 Cr
Long Term Provisions	0	384.73 Cr	2879.67 Cr	3259.41 Cr
Total Non-Current Liabilities	507.8 Cr	682.34 Cr	3138.49 Cr	3399.83 Cr
Trade Payables	2060.95 Cr	1661.15 Cr	2202.32 Cr	1789.23 Cr
Sundry Creditors	2060.95 Cr	1661.15 Cr	2202.32 Cr	1789.23 Cr
Other Current Liabilities	492.52 Cr	597.84 Cr	206.37 Cr	518.02 Cr
Advances received from customers	7.18 Cr	17.66 Cr	23.24 Cr	10.06 Cr
Interest Accrued But Not Due	33 Lk	0	46 Lk	2.08 Cr
Short Term Borrowings	3953.1 Cr	1818.62 Cr	4142.57 Cr	2817.84 Cr
Secured ST Loans repayable on Demands	841.5 Cr	288.75 Cr	1922.78 Cr	1431.99 Cr
Working Capital Loans- Sec	841.5 Cr	288.75 Cr	1922.78 Cr	1431.99 Cr
Short Term Provisions	250.01 Cr	103.36 Cr	436.68 Cr	621.72 Cr
Provision for Tax	139.01 Cr	0	407.02 Cr	603.69 Cr
Total Current Liabilities	6756.58 Cr	4180.97 Cr	6987.94 Cr	5746.81 Cr
Total Liabilities	23189 Cr	21980.6 Cr	28040.6 Cr	28869.5 Cr
Gross Block	6688.91 Cr	5724.9 Cr	6214.72 Cr	4043.49 Cr
Less: Accumulated Depreciation	2216.84 Cr	2139.07 Cr	2527.22 Cr	1624.36 Cr
Net Block	4472.07 Cr	3585.83 Cr	3687.5 Cr	2419.13 Cr
Capital Work in Progress	719.02 Cr	225.15 Cr	239.09 Cr	132.68 Cr
Non Current Investments	4880.89 Cr	6584.35 Cr	8221.77 Cr	13393.4 Cr
Long Term Investment	4880.89 Cr	6584.35 Cr	8221.77 Cr	13393.4 Cr
Unquoted	5198.39 Cr	6965.85 Cr	8603.27 Cr	13807.8 Cr
Long Term Loans & Advances	664.23 Cr	1603 Cr	5800.23 Cr	5012.1 Cr
Other Non Current Assets	59.05 Cr	147.21 Cr	53.78 Cr	170.92 Cr
Total Non-Current Assets	10811.1 Cr	12145.5 Cr	18002.4 Cr	21128.3 Cr
Currents Investments	129.04 Cr	1 Lk	1 Lk	1 Lk
Quoted	100.04 Cr	1 Lk	1 Lk	1 Lk
Unquoted	5198.39 Cr	6965.85 Cr	8603.27 Cr	13807.8 Cr
Inventories	4841.38 Cr	3356.18 Cr	4125.26 Cr	2367.6 Cr
Raw Materials	2596.95 Cr	1505.71 Cr	1755.84 Cr	1102.39 Cr
Work-in Progress	1172.5 Cr	981.39 Cr	1214.87 Cr	268.32 Cr
Finished Goods	277.67 Cr	243.33 Cr	341.29 Cr	277.61 Cr
Packing Materials	255.04 Cr	111.58 Cr	158.45 Cr	170.18 Cr
Stores and Spare	167.63 Cr	145.55 Cr	151.63 Cr	86.47 Cr
Sundry Debtors	5928.01 Cr	3973.24 Cr	4560.26 Cr	3776.59 Cr
Debtors more than Six months	0	66.06 Cr	73.15 Cr	90.53 Cr
Debtors Others	5972.03 Cr	3936.31 Cr	4525.26 Cr	3708.31 Cr
Cash and Bank	386.18 Cr	50.78 Cr	132.14 Cr	94.34 Cr
Cash in hand	10 Lk	12 Lk	3 Lk	5 Lk
Balances at Bank	386.08 Cr	50.66 Cr	132.11 Cr	94.29 Cr
Other Current Assets	532.39 Cr	1894.13 Cr	426.73 Cr	385.74 Cr
Interest accrued on Investments	48.75 Cr	2.32 Cr	3.28 Cr	1.8 Cr
Interest accrued on Debentures	0	0	13.35 Cr	5.41 Cr
Short Term Loans and Advances	560.86 Cr	560.77 Cr	793.83 Cr	1116.92 Cr
Advances recoverable in cash or in kind	179.8 Cr	209.93 Cr	150.85 Cr	168.83 Cr
Advance income tax and TDS	0	0	314.59 Cr	502.07 Cr
Total Current Assets	12377.9 Cr	9835.11 Cr	10038.2 Cr	7741.2 Cr
Net Current Assets (Including Current Investments)	5621.28 Cr	5654.14 Cr	3050.29 Cr	1994.39 Cr
Total Assets	23189 Cr	21980.6 Cr	28040.6 Cr	28869.5 Cr
Contingent Liabilities	887.66 Cr	152.93 Cr	534.26 Cr	1969.15 Cr
Total Debt	3953.1 Cr	1818.62 Cr	4142.57 Cr	2817.84 Cr
Book Value	271.8	292.16	305.76	336.62
Adjusted Book Value	271.8	292.16	305.76	336.62

Consolidated Standalone

FINANCIAL RATIOS (CONSOLIDATED) FOR AUROBINDO PHARMA LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Operational & Financial Ratios
Earnings Per Share (Rs)	91.05	45.2	32.9	54.16
CEPS(Rs)	109.99	64.94	54.14	80.06
DPS(Rs)	4	9	3	4.5
Book NAV/Share(Rs)	374.29	419.46	458.1	509.35
Tax Rate(%)	27.16	21.32	26.21	27.65
Margin Ratios
Core EBITDA Margin(%)	10.98	9.17	7.31	9.77
EBIT Margin(%)	15.38	7.22	5.41	7.81
Pre Tax Margin(%)	15.23	7.12	5.14	7.33
PAT Margin (%)	11.09	5.6	3.79	5.3
Cash Profit Margin (%)	13.26	7.96	6.24	7.85
Performance Ratios
ROA(%)	17.34	7.99	5.29	7.63
ROE(%)	27.81	11.52	7.5	11.18
ROCE(%)	30.33	12.82	9.39	13.76
Asset Turnover(x)	1.56	1.43	1.4	1.44
Sales/Fixed Asset(x)	3.73	3.24	2.95	2.84
Working Capital/Sales(x)	5.31	4.8	5.1	5.17
Efficiency Ratios
Fixed Capital/Sales(x)	0.27	0.31	0.34	0.35
Receivable days	29.37	28.69	30.42	28.34
Inventory Days	62.82	63.29	57.65	55.92
Payable days	50.82	108.6	117.74	133.88
Valuation Parameters
PER(x)	9.68	14.8	15.75	20.12
PCE(x)	8.01	10.3	9.57	13.61
Price/Book(x)	2.36	1.59	1.13	2.14
Yield(%)	0.45	1.35	0.58	0.41
EV/Net Sales(x)	2.06	1.59	1.17	2.2
EV/Core EBITDA(x)	8.95	7.94	7.26	9.98
EV/EBIT(x)	6.84	10.83	10.58	13.68
EV/CE(x)	1.53	1.11	0.74	1.77
M Cap / Sales	2.08	1.67	1.22	2.2
Growth Ratio
Net Sales Growth(%)	7.26	-5.32	5.97	16.68
Core EBITDA Growth(%)	13.02	-17.62	-14.83	59.64
EBIT Growth(%)	83.92	-53.8	-19.54	69.62
PAT Growth(%)	88.51	-50.3	-27.18	64.4
EPS Growth(%)	87.51	-50.36	-27.21	64.62
Financial Stability Ratios
Total Debt/Equity(x)	0.23	0.1	0.18	0.21
Current Ratio(x)	1.86	2.22	1.87	1.95
Quick Ratio(x)	1.01	1.3	1.13	1.14
Interest Cover(x)	100.33	70.98	19.6	16.12
Total Debt/Mcap(x)	0.1	0.06	0.16	0.1

FINANCIAL RATIOS (STANDALONE) FOR AUROBINDO PHARMA LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Operational & Financial Ratios
Earnings Per Share (Rs)	53.13	24.83	21	32.43
CEPS(Rs)	61.46	31.92	28.43	36.78
DPS(Rs)	4	9	3	4.5
Book NAV/Share(Rs)	271.8	292.16	305.76	336.62
Tax Rate(%)	25.76	11.16	23.78	20.93
Margin Ratios
Core EBITDA Margin(%)	25.95	12.82	13.43	20.86
EBIT Margin(%)	26.59	14.58	13.42	24.25
Pre Tax Margin(%)	26.41	14.43	12.53	22.53
PAT Margin (%)	19.61	12.82	9.55	17.82
Cash Profit Margin (%)	22.68	16.48	12.93	20.21
Performance Ratios
ROA(%)	14.56	6.31	4.57	6.66
ROE(%)	21.49	8.81	7.02	10.06
ROCE(%)	23.03	8.52	8.44	11.56
Asset Turnover(x)	0.74	0.49	0.48	0.37
Sales/Fixed Asset(x)	2.47	1.83	2.16	2.08
Working Capital/Sales(x)	2.82	2.01	4.22	5.35
Efficiency Ratios
Fixed Capital/Sales(x)	0.41	0.55	0.46	0.48
Receivable days	134.65	159.2	120.87	142.68
Inventory Days	105.77	131.81	105.97	111.13
Payable days	63.03	128.68	113.35	141.91
Valuation Parameters
PER(x)	16.59	26.94	24.67	33.59
PCE(x)	14.34	20.96	18.22	29.62
Price/Book(x)	3.24	2.29	1.69	3.24
Yield(%)	0.45	1.35	0.58	0.41
EV/Net Sales(x)	3.49	3.63	2.69	6.25
EV/Core EBITDA(x)	11.72	19.1	15.87	23.43
EV/EBIT(x)	13.08	24.76	19.87	25.74
EV/CE(x)	2.38	1.86	1.23	2.95
M Cap / Sales	3.26	3.47	2.37	6
Growth Ratio
Net Sales Growth(%)	18.35	-28.67	13.34	25.88
Core EBITDA Growth(%)	52.58	-54.47	0.95	45.73
EBIT Growth(%)	61.54	-60.81	4.53	51.59
PAT Growth(%)	65.86	-53.27	-15.42	52.97
EPS Growth(%)	65.86	-53.27	-15.42	52.97
Financial Stability Ratios
Total Debt/Equity(x)	0.25	0.11	0.23	0.14
Current Ratio(x)	1.83	2.35	1.44	1.35
Quick Ratio(x)	1.12	1.55	0.85	0.94
Interest Cover(x)	147.2	97.66	15.04	14.16
Total Debt/Mcap(x)	0.08	0.05	0.14	0.04

SHARE HOLDING PATTERN FOR AUROBINDO PHARMA LIMITED

Date	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoters %	48.76	48.76	48.76	48.76	48.76	48.76	48.76	48.76	48.73	48.75
FII %	20.71	21.40	22.30	23.02	24.13	22.45	20.72	18.01	16.73	16.59
DII %	0.00	0.18	0.18	0.20	0.28	0.29	0.29	0.28	0.25	0.31
Public %	10.15	10.20	10.96	10.05	8.31	7.42	6.85	6.87	6.70	6.46

PEER COMPARISON FOR AUROBINDO PHARMA LIMITED

No.	Name
1	AMBALAL SARABHAI ENTERPRISES LTD
2	Cipla Limited
3	Dr. Reddy's Laboratories Limited
4	Procter & Gamble Health Limited
5	J.K.PHARMACHEM LTD
6	Lupin Limited
7	Lyka Labs Limited
8	MESCO PHARMACEUTICALS LTD
9	Morepen Laboratories Limited
10	Piramal Enterprises Limited
11	Torrent Pharmaceuticals Limited
12	Abbott India Limited
13	GlaxoSmithKline Pharmaceuticals Limited
14	Sanofi India Limited
15	Pfizer Limited
16	Bliss GVS Pharma Limited
17	Alembic Limited
18	Unichem Laboratories Limited
19	AstraZeneca Pharma India Limited
20	GUJARAT THEMIS BIOSYN LTD
21	JB Chemicals & Pharmaceuticals Limited
22	TTK Healthcare Limited
23	Jagsonpal Pharmaceuticals Limited
24	Gufic Biosciences Limited
25	Sequent Scientific Limited
26	Albert David Limited
27	IOL Chemicals and Pharmaceuticals Limited
28	Wanbury Limited
29	Kopran Limited
30	Aarti Drugs Limited
31	Orchid Pharma Limited
32	Biofil Chemicals & Pharmaceuticals Limited
33	Marksans Pharma Limited
34	IPCA Laboratories Limited
35	Kilitch Drugs (India) Limited
36	Krebs Biochemicals and Industries Limited
37	Neuland Laboratories Limited
38	Ind-Swift Limited
39	Hester Biosciences Limited
40	Parenteral Drugs (India) Limited
41	Sun Pharmaceutical Industries Limited
42	Hikal Limited
43	Caplin Point Laboratories Limited
44	Aurobindo Pharma Limited
45	Natco Pharma Limited
46	Bal Pharma Limited
47	BDH INDUSTRIES LTD
48	Venus Remedies Limited
49	Jubilant Pharmova Limited
50	Themis Medicare Limited

CORPORATE ACTIONS FOR AUROBINDO PHARMA

Exchange Date	Purpose	Book Closure Dates
BSE 31-Jul-2024	Board Meeting - Quarterly Results	10-Aug-2024
BSE 15-Jul-2024	Board Meeting - Buy Back of Shares	18-Jul-2024
BSE 16-May-2024	Board Meeting - Audited Results	25-May-2024
BSE 20-Feb-2024	Dividend - Second Interim Dividend
BSE 01-Feb-2024	Board Meeting - Quarterly Results	10-Feb-2024
BSE 20-Nov-2023	Dividend - Interim Dividend
BSE 13-Nov-2023	SAST - Board has approved the acquisition entire equity share capital of Theranym Biologics Private Limited, a 100% stepdown subsidiary, to make it a direct subsidiary.
BSE 27-Oct-2023	Board Meeting - Interim Dividend & Quarterly Results	09-Nov-2023
BSE 03-Aug-2023	Board Meeting - Quarterly Results	12-Aug-2023
BSE 28-Jul-2023	Book Closure - A.G.M.	23-Aug-2023 25-Aug-2023
BSE 28-Jul-2023	AGM - A.G.M.	25-Aug-2023 25-Aug-2023
BSE 26-Jul-2023	SAST - Company has incorporated a new step-down subsidiary in Russia
BSE 18-May-2023	Board Meeting - Audited Results	27-May-2023
BSE 17-Feb-2023	Dividend - Interim Dividend
BSE 31-Jan-2023	Board Meeting - Quarterly Results & Interim Dividend	09-Feb-2023
BSE 31-Oct-2022	Board Meeting - Quarterly Results	12-Nov-2022
BSE 03-Aug-2022	Board Meeting - Quarterly Results	11-Aug-2022
BSE 07-Jul-2022	Book Closure - A.G.M.	29-Jul-2022 02-Aug-2022
BSE 07-Jul-2022	AGM - A.G.M.	02-Aug-2022 02-Aug-2022
BSE 20-Jun-2022	SAST - This is to inform you that the Board of Directors of the Company at its meeting held on June 17, 2022, has approved the acquisition of 51% equity shares in GLS Pharma Limited, operating in oncology business and having manufacturing facility in Hyderabad for a total consideration of INR 28,05,00,000. The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requiremen...
BSE 06-Jun-2022	Dividend - Interim Dividend
BSE 20-May-2022	Board Meeting - Audited Results & Fourth Interim Dividend	30-May-2022
BSE 18-Feb-2022	Dividend - Third Interim Dividend of Rs.1.50/- (150%)
BSE 31-Jan-2022	Board Meeting - Third Interim Dividend & Quarterly Results	09-Feb-2022
BSE 17-Nov-2021	Dividend - Rs.1.5000 per share (150%) Second Interim Dividend
BSE 01-Nov-2021	Board Meeting - Quarterly Results & Second Interim Dividend	08-Nov-2021

CORPORATE ANNOUNCEMENTS FOR AUROBINDO PHARMA

Exchange Date	Category File	Description
BSE 29-Oct-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Press Release / Media Release Press Release - Honble Prime Minister Shri Narendra Modi inaugurates Lyfius Pharmas Flagship Pencillin-G-Facility at Kakinada Andhra Pradesh.
BSE 25-Oct-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Updates on Acquisition We refer to our letter dated September 18 2024 informing that the Company entered into binding agreement with GLS Pharma Limited (GLS) a subsidiary of the Company and its promoters for acquisition of balance 590361 equity sharesof INR 10/- each (49% of GLS) for a purchase consideration of INR22.50 crores. The aforementioned acquisition has been completed on October 25 2024 and GLS has become wholly owned subsidiary of the Company.
BSE 22-Oct-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation of loss of share certificate
BSE 07-Oct-2024	General Announcements FILE	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Submission of certificate under Regulation 74 (5) of SEBI (Depositories Participants) Regulations 2018 for the Quarter ended 30th September 2024
BSE 05-Oct-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Diversification / Disinvestment Intimation of sale of entire 24.5% shares held in Novagen BBBEE Invest Co (Pyt) Limited South Africa a joint venture of a step-down subsidiary Autogen South Africa (Pty) Ltd.
BSE 05-Oct-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Diversification / Disinvestment Intimation of sale of entire 50% shares in Novagen Pharma (Pty) Limited South Africa a joint venture company.
BSE 04-Oct-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation of loss of share certificate.
BSE 01-Oct-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Press Release / Media Release Aurobindo Pharma receives USFDA approval for Cephalexin Tables USP 250 mg and 500 mg
BSE 30-Sep-2024	General Announcements FILE	Completion Of US FDA Inspection At Unit II Of Apitoria Pharma Private Limited A Wholly Owned Subsidiary Of The Company Intimation of completion of US FDA Audit at Unit II of Apitoria Pharma Private Limited a wholly owned subsidiary of the Company.
BSE 25-Sep-2024	Intimation FILE	Closure of Trading Window Intimation of Closure of Trading window.
BSE 19-Sep-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Intimation investors meet to be held on September 24 2024.
BSE 18-Sep-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Acquisition Intimation of entering into a binding agreement for acquiring balance 49% equity shares in GLS Pharma Limited a subsidiary of the Company.
BSE 18-Sep-2024	General Announcements FILE	New Injectable Facility Of Eugia Steriles Private Limited A 100% Stepdown Subsidiary Of The Company Receives Establishment Inspection Report (EIR) From The United States Food And Drug Administration Submission of receipt of Establishment Inspection Report from USFDA for new injectable facility of Eugia Steriles Private Limited a 100% step-down subsidiary company.
BSE 13-Sep-2024	General FILE	Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Life Insurance Corporation of India
BSE 13-Sep-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Newspaper Publication Submission of copy of notice published in newspapers with regard to transfer of shares to IEPF.
BSE 11-Sep-2024	General Announcements FILE	New Injectable Facility Of Eugia Steriles Private Limited A 100% Stepdown Subsidiary Of The Company Receives Its First Product Approval By The United States Food And Drug Administration (US FDA) Intimation of receipt of first product approval from USFDA for Eugia Steriles Private Limited a 100% stepdown subsidiary.
BSE 30-Aug-2024	Outcome FILE	Shareholder Meeting / Postal Ballot-Scrutinizer''s Report Submission of Voting Results of 37th Annual General Meeting of the company held on August 29 2024
BSE 29-Aug-2024	Outcome FILE	Shareholder Meeting / Postal Ballot-Outcome of AGM Submission of proceedings of 37th Annual General meeting of the Company held on August 29 2024.
BSE 29-Aug-2024	General Announcements FILE	The Company Has Received An Order From The Deputy Commissioner Punjagutta (ST) STU-1 Of GST Hyderabad Passed For The Financial Year 2019-20 The Company has received an order from the Deputy Commissioner Punjagautta(ST) STU-1 of GST Hyderabad.
BSE 28-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Intimation of Investor meet
BSE 27-Aug-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation of loss of share certificates.
BSE 26-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Closure of Buy Back Submission of Certificate of Extinguishments 51 36 986 equity shares of Re. 1 each bought back under the Companys Buyback offer.
BSE 21-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Newspaper Publication Submission of post buyback public announcement.
BSE 16-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Earnings Call Transcript Submission of Transcript of Earning call on unaudited financial results of Q1 2024-25.
BSE 16-Aug-2024	General Announcements FILE	Unit III Of Eugia Pharma Specialities Ltd. Receives Warning Letter From US FDA Intimation of receipt of Warning Letter from US FDA for Unit III of Eugia Pharma Specialities Limited a wholly owned subsidiarity of the Company
BSE 13-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Intimation of investor meet (Motilal Oswal) on 20.08.2024.
BSE 13-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Intimation of investor meeting (IIFL Capital) on 21.08.2024.
BSE 13-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Intimation of investor meet (IIFL Capital) on 20.08.2024.
BSE 12-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome Pursuant to Regulation 30 of SEBI Listing Regulations and further to our letter dated August 5 2024 please note that the audio recording of the earnings call on the Unaudited Financial Results for the first quarter ended June 30 2024 held on August 12 2024 at 8.30 AM (IST) has been uploaded on our website on the following web-link:https://www.aurobindo.com/investors/disclosures-under-regulation-46/investor-meet/audio-or-video-recordings
BSE 12-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Newspaper Publication Submission of unaudited financial results for the quarter ended June 30 2024 published in newspapers.

INSIDER TRADING FOR AUROBINDO PHARMA

Exchange Dates	Activity	Qty & Price (%)	Person / Organisation
BSE 20-Mar-2024 22-Mar-2024	Sell Market	6,000 @ 0.00 (0.00 %)	A Janardhana Kamath
BSE 29-Feb-2024 29-Feb-2024	Sell Market	1,000 @ 0.00 (0.00 %)	Pavankumar PS
BSE 15-Feb-2024 21-Feb-2024	Sell Market	1,000 @ 0.00 (0.00 %)	Pavankumar PS
BSE 15-Feb-2024 15-Feb-2024	Sell Market	5,000 @ 0.00 (0.01 %)	Ambati Rama Mohan Rao
BSE 19-Feb-2024 19-Feb-2024	Sell Market	5,000 @ 0.00 (0.00 %)	K Nagaraju
BSE 27-Dec-2023 29-Dec-2023	Sell Market	1,000 @ 0.00 (0.00 %)	KR Vijayapal Reddy
BSE 04-Dec-2023 04-Dec-2023	Sell Market	3,000 @ 0.00 (0.00 %)	S Sadananda Reddy
BSE 21-Nov-2023 23-Nov-2023	Sell Market	1,600 @ 0.00 (0.00 %)	Mahesh Bhaskar Shinde
BSE 23-Nov-2023 23-Nov-2023	Sell Market	7,000 @ 0.00 (0.01 %)	S Sadananda Reddy
BSE 22-Nov-2023 22-Nov-2023	Sell Market	2,100 @ 0.00 (0.00 %)	Thomas Koshy V
BSE 22-Nov-2023 24-Nov-2023	Sell Market	6,009 @ 0.00 (0.00 %)	Venkata Narayana Reddy Jayampu
BSE 29-Sep-2023 29-Sep-2023	Sell Market	6,000 @ 0.00 (0.00 %)	Ambati Rama Mohan Rao
BSE 29-Sep-2023 29-Sep-2023	Sell Market	1,096 @ 0.00 (0.00 %)	Kannaiah Gandala
BSE 13-Sep-2023 29-Sep-2023	Sell Market	1,800 @ 0.00 (0.00 %)	Gita Rao
BSE 29-Sep-2023 29-Sep-2023	Sell Market	2,025 @ 0.00 (0.00 %)	Ch S S S Murali
BSE 29-Sep-2023 29-Sep-2023	Sell Market	6,000 @ 0.00 (0.00 %)	Venugopalan Muralidharan
BSE 29-Sep-2023 29-Sep-2023	Sell Market	5,000 @ 0.00 (0.00 %)	S Sadananda Reddy
BSE 15-Sep-2023 15-Sep-2023	Sell Market	3,000 @ 0.00 (0.00 %)	V SUBBA RAO
BSE 13-Sep-2023 13-Sep-2023	Sell Market	1,700 @ 0.00 (0.00 %)	Salgunan K C
BSE 07-Sep-2023 11-Sep-2023	Sell Market	5,000 @ 0.00 (0.00 %)	Naga Prasad Vishnubhotla
BSE 25-Aug-2023 30-Aug-2023	Sell Market	4,000 @ 0.00 (0.00 %)	Veerabhadra Srinivas Tatavarthi
BSE 28-Jun-2023 28-Jun-2023	Sell Market	2,250 @ 0.00 (0.00 %)	Ramu Guntupalli
BSE 28-Mar-2023 31-Mar-2023	Sell Market	2,500 @ 0.00 (0.00 %)	Srinivasa Rao Karimikonda
BSE 14-Sep-2022 14-Sep-2022	Sell Market	20,000 @ 0.00 (0.00 %)	Yugandhar Puvvala
BSE 26-Aug-2022 26-Aug-2022	Sell Market	5,000 @ 0.00 (0.00 %)	Yugandhar Puvvala
BSE 18-Feb-2022 18-Feb-2022	Sell Market	3,749 @ 0.00 (0.00 %)	G Madhava Ram Prasad
BSE 31-Dec-2021 31-Dec-2021	Sell Market	1,580 @ 0.00 (0.00 %)	Rajul Manoranjan
BSE 31-Dec-2021 31-Dec-2021	Sell Market	1,446 @ 0.00 (0.00 %)	Amarnath Govula
BSE 29-Dec-2021 31-Dec-2021	Sell Market	1,450 @ 0.00 (0.00 %)	Aruna Rani Vavilala
BSE 27-Dec-2021 27-Dec-2021	Sell Market	2,145 @ 0.00 (0.00 %)	Veera Venkata Ravindra Nageshwar Rao

BULK BLOCK DEALS FOR AUROBINDO PHARMA LIMITED

Exchange Dates	Activity	Qty & Price (%)	Person / Organisation
BSE 25-Jan-2024	Sell BLOCK	150,001 @ 1160.10	BNP PARIBAS ARBITRAGE
BSE 25-Jan-2024	Sell BLOCK	1,484,323 @ 1160.10	BNP PARIBAS ARBITRAGE
BSE 25-Jan-2024	Buy BLOCK	106,480 @ 1160.10	MARSHALL WACE INVESTMENT STRATEGIES - EUREKA FUND
BSE 25-Jan-2024	Buy BLOCK	15,950 @ 1160.10	MARSHALL WACE INVESTMENT STRATEGIES - SYSTEMATIC ALPHA PLUS FUND
BSE 25-Jan-2024	Buy BLOCK	27,571 @ 1160.10	MARSHALL WACE INVESTMENT STRATEGIESGTOPS FUND
BSE 25-Jan-2024	Buy BLOCK	1,484,323 @ 1160.10	SOCIETE GENERALE
BSE 25-Oct-2022	Sell BLOCK	277,213 @ 524.50	ISHARES CORE EMERGING MARKETS MAURITIUS CO
BSE 25-Oct-2022	Buy BLOCK	277,213 @ 524.50	ISHARES CORE MSCI EMERGING MARKETS ETF
BSE 17-Oct-2022	Sell BLOCK	435,602 @ 514.05	ISHARES CORE EMERGING MARKETS MAURITIUS CO
BSE 17-Oct-2022	Buy BLOCK	435,602 @ 514.05	ISHARES CORE MSCI EMERGING MARKETS ETF
BSE 11-Oct-2022	Sell BLOCK	319,465 @ 535.45	ISHARES CORE EMERGING MARKETS MAURITIUS CO
BSE 11-Oct-2022	Buy BLOCK	319,465 @ 535.45	ISHARES CORE MSCI EMERGING MARKETS ETF
BSE 19-Sep-2022	Sell BLOCK	217,295 @ 533.10	ISHARES CORE EMERGING MARKETS MAURITIUS CO
BSE 19-Sep-2022	Buy BLOCK	217,295 @ 533.10	ISHARES CORE MSCI EMERGING MARKETS ETF
BSE 01-Aug-2022	Sell BLOCK	311,433 @ 547.00	ISHARES INDIA INDEX MAURITIUS COMPANY
BSE 01-Aug-2022	Buy BLOCK	311,433 @ 547.00	ISHARES MSCI INDIA ETF
BSE 18-Jul-2022	Sell BLOCK	313,304 @ 548.75	ISHARES INDIA INDEX MAURITIUS COMPANY
BSE 18-Jul-2022	Buy BLOCK	313,304 @ 548.75	ISHARES MSCI INDIA ETF
BSE 04-May-2022	Buy BLOCK	354,384 @ 642.50	ISHARES CORE MSCI TOTAL INTERNATIONAL STOCK ETF
BSE 04-May-2022	Sell BLOCK	354,384 @ 642.50	ISHARES CORE TOTAL INTERNATIONAL STOCK MAURITIUS CO
BSE 20-Oct-2021	Sell BLOCK	264,506 @ 712.55	ISHARES EMERGING MARKETS INDEX MAURITIUS CO
BSE 20-Oct-2021	Buy BLOCK	264,506 @ 712.55	ISHARES MSCI EMERGING MARKETS ETF
BSE 11-Oct-2021	Sell BLOCK	264,506 @ 714.75	ISHARES EMERGING MARKETS INDEX MAURITIUS CO
BSE 11-Oct-2021	Buy BLOCK	264,506 @ 714.75	ISHARES MSCI EMERGING MARKETS ETF
BSE 23-Sep-2021	Sell BLOCK	269,231 @ 731.10	ISHARES EMERGING MARKETS INDEX MAURITIUS CO
BSE 23-Sep-2021	Buy BLOCK	269,231 @ 731.10	ISHARES MSCI EMERGING MARKETS ETF

DIVIDEND BY AUROBINDO PHARMA LIMITED

Ex Dividend Date	Dividend Type	Dividend
20-Feb-2024	INTERIM DIVIDEND	1.5
20-Nov-2023	INTERIM DIVIDEND	3
17-Feb-2023	INTERIM DIVIDEND	3
06-Jun-2022	INTERIM DIVIDEND	4.5
18-Feb-2022	INTERIM DIVIDEND	1.5
17-Nov-2021	INTERIM DIVIDEND	1.5
27-Aug-2021	INTERIM DIVIDEND	1.5
22-Feb-2021	INTERIM DIVIDEND	1.5
23-Nov-2020	INTERIM DIVIDEND	1.25